Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma.
Eugene Kennedy
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Gabriela R. Rossi
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics